Printer Friendly

NATIONAL RESEARCH COUNCIL CANADA APPROVES ADDITIONAL CDN. $250,000 TO SPECTRAL DIAGNOSTICS INC.

NATIONAL RESEARCH COUNCIL CANADA APPROVES ADDITIONAL CDN. $250,000 TO
 SPECTRAL DIAGNOSTICS INC.
 TORONTO, Oct. 1 /CNW/ - Spectral Diagnostics Inc. (NASDAQ: DIAGF), Toronto, reported today that the National Research Council Canada (NRCC), an agency of the Canadian government, has approved a new financial contribution of approximately Cdn. $250,000 to the company for research and development of Spectral's next generation, in-vitro, diagnostic cardiac panel for the definitive diagnosis within minutes of heart ailments, including heart attack.
 This funding extends for a period of 12 months, and follows a contribution of Cdn. $221,504 provided by NRCC in October 1991, and concluded on March 31, 1992.
 In making the announcement, Douglas C. Ball, chairman of Spectral Diagnostics, said, "We are particularly proud of the newly approved financial assistance from the National Research Council Canada which not only provides support in the development of Spectral's next generation of cardiac diagnostics but, in our view, represents their continued confidence in Spectral's research and development activities."
 As previously reported, clinical trials are presently under way for Spectral's first generation proprietary, in-vitro diagnostic cardiac panel.
 Spectral Diagnostics Inc. has developed a systems approach to cardiac diagnostics that includes its proprietary cardiac panel. The cardiac panel distinguishes, for the first time, heart from non-heart ailments and unstable angina from a myocardial infarction (heart attack) - without the use or dependence on expensive laboratory equipment. Spectral's cardiac panel, slightly larger than a credit card, is easy to use, requires only a few drops of a patient's blood and provides a differential diagnosis in approximately eight minutes. Patent applications have been filed in 18 countries. The cardiac panel in combination with Spectral's library of cardiac proteins and antibodies will complete the systems approach to cardiac diagnostics.
 Spectral's common shares are listed on the NASDAQ exchange in the United States and the Canadian Dealing Network in Canada. Spectral's trading symbols are DIAGF (common shares) and DIAGWF (redeemable warrants) on the NASDAQ exchange and SPTR (common shares) and SPTR.WT (redeemable warrants) on the Canadian Dealing Network.
 For Further information: C. Ball, chairman and CEO, or Dr. George Jackowski, president and director-research and development of Spectral Diagnostics (416) 626-3233; or Irving L. Straus of Straus Corporate Communications (212) 768-2477, for Spectral Diagnostics
 (DIAGF)
 -0- 10/01/92


CO: SPECTRAL DIAGNOSTICS INC. IN: MTC ST: -- -- X989 10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:387
Previous Article:MERRILL CORPORATION ANNOUNCES PARTNERSHIP AGREEMENT WITH BURRUPS/ST. IVES, UK.
Next Article:TEXTRON TO REDEEM ITS 7-1/2 PERCENT SINKING FUND DEBENTURES DUE 1997
Topics:


Related Articles
SPECTRAL DIAGNOSTICS INC. RAISES AN ADDITIONAL $1.2 MILLION
NATIONAL RESEARCH COUNCIL CANADA APPROVALS CDN. $348,000 TO SPECTRAL DIAGNOSTICS
SPECTRAL DIAGNOSTICS CALLS 736,200 REDEEMABLE COMMON STOCK PURCHASE WARRANTS TO PURCHASE SHARES FOR US$8 PER SHARE; REALIZES US$5,889,600
LEE D. FLOWERS, VICE PRESIDENT, BAXTER DIAGNOSTICS INC., A SUBSIDIARY OF BAXTER INTERNATIONAL, APPOINTED DIRECTOR OF SPECTRAL DIAGNOSTICS INC.
SPECTRAL DIAGNOSTICS TO ACQUIRE PRIMECARE B.V. AND ITS PATENTED MEMBRANE TECHNOLOGY FOR RAPID PLASMA SEPARATION FROM WHOLE BLOOD
SPECTRAL DIAGNOSTICS INC. ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH NIHON MEDI-PHYSICS OF JAPAN FOR THE EXCLUSIVE NEGOTIATION OF JAPANESE...
SPECTRAL DIAGNOSTICS APPOINTS EVP AND OPERATIONS OFFICER, POSITIONING COMPANY FOR COMMERCIALIZATION OF ITS CARDIAC DIAGNOSTIC PRODUCTS IN 1994
SPECTRAL DIAGNOSTICS INC. COMPLETES ACQUISITION OF PRIMECARE B.V. AND ITS UNIQUE PATENTED MEMBRANE TECHNOLOGY FOR RAPID PLASMA SEPARATION FROM WHOLE...
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THIRD FISCAL QUARTER AND NINE MONTHS ENDED DEC. 31, 1993
Spectral Diagnostics Inc. Receives FDA Marketing Clearance For Cardiac STATus(TM) Controls For CK-MB/Myoglobin

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters